Fjarde AP Fonden Fourth Swedish National Pension Fund Increases Stake in DaVita Inc. $DVA

Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in shares of DaVita Inc. (NYSE:DVA) by 2.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,139 shares of the company’s stock after acquiring an additional 200 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in DaVita were worth $1,302,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in DVA. Doma Perpetual Capital Management LLC increased its position in shares of DaVita by 172.3% in the first quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock valued at $44,110,000 after buying an additional 182,476 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in DaVita during the second quarter worth $21,554,000. Northern Trust Corp boosted its stake in DaVita by 20.2% during the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock worth $136,240,000 after buying an additional 149,858 shares during the last quarter. Nuveen LLC acquired a new position in DaVita during the first quarter worth $20,218,000. Finally, Amundi lifted its stake in shares of DaVita by 16.0% in the 1st quarter. Amundi now owns 517,690 shares of the company’s stock valued at $79,584,000 after purchasing an additional 71,304 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on DVA. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a research note on Wednesday, October 8th. Barclays cut their price target on DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a report on Thursday. Truist Financial set a $140.00 price target on DaVita in a report on Tuesday, October 14th. Wall Street Zen cut DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Finally, Bank of America decreased their target price on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday, September 10th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $151.75.

DaVita Trading Up 0.1%

DaVita stock opened at $118.84 on Friday. The stock has a market capitalization of $8.50 billion, a price-to-earnings ratio of 12.24, a PEG ratio of 0.91 and a beta of 1.13. The stock has a 50 day moving average of $130.78 and a two-hundred day moving average of $136.66. DaVita Inc. has a twelve month low of $115.39 and a twelve month high of $179.60.

DaVita (NYSE:DVA) last issued its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The business had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.43 billion. DaVita had a return on equity of 815.62% and a net margin of 5.80%.The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the company posted $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Equities analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.